Insulin Secretion

Insulin Secretion

Insulin secretion is how pancreatic beta cells release insulin into the blood, mainly when blood sugar rises after eating. It happens in two phases: a fast first phase of about ten minutes, when ready-made insulin granules are released, and a longer second phase using newly made insulin. The incretin hormones GLP-1 and GIP amplify glucose-triggered insulin release and account for up to 70% of insulin released after meals, through what is called the incretin effect. Loss of this incretin boost is a hallmark of type 2 diabetes and contributes to poor blood sugar control after meals.

Inside the beta cell, insulin release is controlled by a chain of signals. Glucose enters through GLUT transporters and is broken down to make ATP. ATP closes ATP-sensitive potassium channels, which changes the charge across the cell membrane and lets calcium flow in through voltage-gated calcium channels. The calcium makes insulin-filled granules fuse with the cell membrane and release their hormone. Incretin hormones strengthen this pathway by raising cyclic AMP inside the cell, which boosts each step without triggering insulin release when glucose is absent. That property keeps the risk of hypoglycemia low.

Clinical Relevance to Retatrutide

Retatrutide, a triple agonist of the GLP-1, GIP and glucagon receptors, boosts insulin release in several complementary ways. GLP-1 and GIP receptor activation on beta cells directly strengthens glucose-triggered insulin release, while glucagon receptor activity may support beta cell function indirectly through better handling of metabolic fuels. In clinical trials, retatrutide improved blood sugar control in ways that fit a strong boost to insulin release, especially after meals. Because incretin-driven insulin release depends on glucose, the risk of hypoglycemia with retatrutide stays low, unlike older insulin-releasing drugs such as sulfonylureas.